Investing in Healthspan Extension
“Let’s aim to help people live much longer than we can today. And if we only end up helping them live really well for a long time, that will be great too.”
What Lifespan Vision looks for
We back exceptional founders building therapeutics and technologies aimed at aging and age-related disease, with the goal of extending healthy lifespan
Our core focus is pre-seed, seed, and Series A. We believe early capital has the most impact on a company's trajectory. We're well-capitalized to support our portfolio companies well beyond the first check, through later rounds as they scale.
Deep relationships across academia, industry and financial markets let us connect the right people at the right time - often accelerating a company's timeline or surfacing possibilities a founder hadn't considered.
Our investment focus areas
Meet the Lifespan Vision team
Andrew Worden
Founder of GameChange Solar (2012), which grew from a startup into a global leader with over $1B in profitable sales by 2022, driving down the cost of solar power generation worldwide. Before that, Andrew founded Soltas Energy, building and selling ten solar power plants by 2014. Earlier in his career, he oversaw a 170+ company global investment portfolio as General Partner of Barron Partners LP. Graduated from Harvard with a degree in Physical Sciences, cross-enrolled in Engineering at MIT and Finance/Marketing at MIT Sloan. Andrew funds longevity research through the Andrew Worden SEAS Dean's Innovation Fund at Harvard, and directs the Barron Charitable Foundation.
Harry Robb
Leads the investment team at LifeSpan Vision Ventures, conducting analysis across the longevity biotech sector to guide investment decisions and sits on the Boards of several LifeSpan companies. Previously an investment manager at Longevity.Technology, where he built the platform's global institutional and private investor network and developed a deal pipeline valued at roughly $300 million. Interned in investment roles at FLYFWD Ventures and in business development at OXWASH. Holds an MSc in Applied Biosciences and Biotechnology from Imperial College London and a BSc in Biomedical Science from King's College London.
Altar Munis, PhD
Venture capital professional bridging life sciences and healthcare innovation. Altar completed postdoctoral research at Oxford and held scientific and strategic roles at AstraZeneca and Eisai across oncology, neurology, and immunology. At Eisai, he sourced and evaluated investment opportunities in life science therapeutics, techbio, and AI, leading due diligence and market analysis. At LifeSpan, he applies a data-driven lens to venture investing focused on regenerative medicine and healthy aging. Holds a BSc in Chemical and Biomolecular Engineering from Johns Hopkins and a PhD in Immunology and Gene Therapy from UCL.
Academic Roots
